App-Quantinova.ai

Novel Sjogre-s Autoantibodies Found in fibromyalgia Patients with Sicca and/or Xerostomia

A. Lichtbroun - European Workshop for Rheumatology Research (EWRR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Dental and Oral Health

Fibromyalgia

Hydroxychloroquine

Hydroxychloroquine Retinopathy: Update on Application of The 2011 Screening Guidelines in An Academic Practice

S.M.A. Shah - European Workshop for Rheumatology Research (EWRR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

USE OF TNF INHIBITORS IS ASSOCIATED WITH A REDUCED RISK OF DIABETES IN RA PATIENTS

S. Lillegraven - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

Hydroxychloroquine

COST-EFFECTIVENESS OF BIOLOGIC VERSUS CONVENTIONAL COMBINATION TREATMENT IN EARLY RHEUMATOID ARTHRITIS: 2-YEAR RESULTS OF THE RANDOMISED CONTROLLED SWEFOT TRIAL

J. Eriksson - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

A PRELIMINARY INVESTIGATION OF TREAT-TO-TARGET CRITERIA USING BSAS, RAPID3 AND PHYSICIAN GLOBAL IN BEHCE-S SYNDROME

Y. Yazici - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Behcet disease

Hydroxychloroquine

INEFFICACY OF HYDROXYCHOROQUINE IN PRIMARY Sjogren's Syndrome: RESULTS AT 12 MONTHS OF THE RANDOMIZED PLACEBO-CONTROLLED TRIAL OF PLAQUENIL IN PRIMARY Sjogren's Syndrome

J. E. Gottenberg - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

Hydroxychloroquine

RANDOMIZED COMPARISON OF TRIPLE DMARD THERAPY WITH METHOTREXATE MONO-THERAPY

P. H. P. De Jong - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Hydroxychloroquine

RETINOTOXICITY OF HYDROXYCHLOROQUINE; IS IT POSSIBLE TO DEMONSTRATE BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY BEFORE DEVELOPMENT? A CROSS SECTIONAL INVESTIGATION

H. F. Cay - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

ICG-ENHANCED FLUORESCENCE OPTICAL IMAGING DETECTS TYPICAL INFLAMMATORY CHANGES IN ASYMPTOMATIC SUBJECTS WITH ELEVATED RHEUMATOID FACTOR OR ANTI-CCP ANTIBODIES

S. G. Werner - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

A NATION-WIDE REVIEW OF PATIENTS WITH RHEUMATOID ARTHRITIS IN FINLAND

K. J. Aaltonen - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

SLEQOL IS RESPONSIVE TO CHANGES IN HEALTH-RELATED QUALITY OF LIFE DUE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

K. P. Leong - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

PREDICTORS OF INTENSIVE ANTI-RHEUMATIC THERAPY IN EARLY CARE FOR RHEUMATOID ARTHRITIS

L. Chiarelli - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

REUMA.PT/LES: THE EXPERIENCE OF TWO CENTRAL HOSPITALS IN LISBON

S. I. Sousa - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

SUCCESS IN THE CITY: THE NORWICH EXPERIENCE OF A NURSE LED TREATMENT ESCALATION CLINIC FOR NEWLY DIAGNOSED ADULT RHEUMATOID ARTHRITIS PATIENTS

H. Hasthorpe - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Rheumatoid arthritis

Hydroxychloroquine

APPROACHES TO TREATMENT OF WEBER-CHRISTIAN DISEASE

B. S. Belov - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

TOCILIZUMAB AS A THERAPEUTIC OPTION FOR RHUPUS PATIENTS REFRACTORY TO CONVENTIONAL THERAPY

D. Rossi - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

THE INFLUENCE OF ANTI-MALARIAL DRUGS (HYDROXYCHLOROQUINE AND QUINACRINE) ON THE INITIATION OF INTERFERON-ALFA PRODUCTION THROUGH TLR-9 PATHWAY

O. Jin - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DISEASE ACTIVITY AT THREE MONTHS IS AN EXCELLENT PREDICTOR OF LONG-TERM TREATMENT FAILURE IN ACTIVELY TREATED RHEUMATOID ARTHRITIS PATIENTS, 5-YEAR RESULTS OF THE NEO-RACO TRIAL

V. Rantalaiho - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Rheumatoid arthritis

Hydroxychloroquine

OUTCOMES OF TWO YEARS OF REMISSION STEERED TREATMENT IN EARLY ARTHRITIS PATIENTS

L. Heimans - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

CLINICAL USEFULNESS OF SERUM LEVEL OF ADALIMUMAB, IN PATIENTS WITH RHEUMATOID ARTHRITIS

J. Rosas - European League Against Rheumatism (EULAR) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Filters

1151 Abstracts